CDK4 and cancer: Taken together, these results indicate that the lack of cooperativity, and, in certain sequential combinations, detriment in cancer cell killing when CDK4/6 inhibitors are combined with cytotoxic drugs are likely a class effect of CDK4/6 inhibitors.